Natriuretic peptide-guided levosimendan therapy for heart failure: A promising new approach

International Journal of Cardiology

Volumn 128, Issue 1, 2008, Pages 91-93

  Giamouzis, Grigorios ^a   Giannakoulas, Georgios ^b   Tsarpalis, Konstantinos ^c   Agha, Syed A ^a   Georgiopoulou, Vasiliki ^a   Kalogeropoulos, Andreas ^a   Karvounis, Haralambos ^b   Butler, Javed ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

Decompensated heart failure; Dobutamine; Levosimendan

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DOBUTAMINE; LEVOSIMENDAN; NESIRITIDE;

ACUTE HEART FAILURE; ARTICLE; COMORBIDITY; DRUG EFFECT; DRUG UTILIZATION; HORMONE BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SYMPATHETIC TONE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; CARDIOTONIC AGENTS; DOBUTAMINE; HEART FAILURE; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PYRIDAZINES; TIME FACTORS;

EID: 46149083952     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.01.034     Document Type: Article

References (16)

1. Cavusoglu Y., Tek M., Birdane A., et al. Both levosimendan and dobutamine treatments result in significant reduction of NT-proBNP levels, but levosimendan has better and prolonged neurohormonal effects than dobutamine. Int J Cardiol 127 (2007) e188-e191
2. Kyrzopoulos S., Adamopoulos S., Parissis J.T., et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol 99 (2005) 409-413
3. Mavrogeni S., Giamouzis G., Papadopoulou E., et al. A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail 13 (2007) 556-559
4. Giannakoulas G., Giannoglou G., Vassilikos V., et al. Clinical significance of acute neurohormonal response after levosimendan treatment. Am J Cardiol 98 (2006) 1123-1124
5. Parissis J.T., Adamopoulos S., Farmakis D., et al. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 92 (2006) 1768-1772
6. Parissis J.T., Farmakis D., and Kremastinos D.T. Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long?. Eur J Heart Fail 8 (2006) 215
7. Butler J., Giamouzis G., and Giannakoulas G. A struggle to SURVIVE: to abandon or not to abandon levosimendan?. Cardiovasc Drugs Ther 21 (2007) 401-402
8. Butler J., Young J.B., Abraham W.T., et al. Beta-blocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol 47 (2006) 2462-2469
9. Patel P., White D.L., and Deswal A. Translation of clinical trial results into practice: temporal patterns of beta-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. Am Heart J 153 (2007) 515-522
10. Parissis J.T., Farmakis D., and Kremastinos D.T. Anti-inflammatory effects of levosimendan in decompensated heart failure: impact on weight loss and anemia. Am J Cardiol 95 (2005) 923-924
11. Parissis J.T., Adamopoulos S., Antoniades C., et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93 (2004) 1309-1312
12. Paraskevaidis I.A., Parissis J.T., and Th Kremastinos D. Anti-inflammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Cardiovasc Hematol Agents 3 (2005) 243-247
13. Mebazaa A., Nieminen M.S., Packer M., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. Jama 297 (2007) 1883-1891
14. Spargias K.S., Anifantakis A., Papadakis M., et al. Preliminary clinical experience with the repetitive administration of levosimendan in patients with end-stage heart failure. Ital Heart J 4 Suppl 2 (2003) 45S-49S
15. Sargento L., Brito D., Matias J.S., and Madeira H. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up. Rev Port Cardiol 26 (2007) 717-726
16. Yancy C.W., Krum H., Massie B.M., et al. The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. Am Heart J 153 (2007) 478-484